Dr. Been does an excellent job of objectively explaining the results PR'd today. Primary endpoint trend toward significance, but secondary endpoint is statistically significant and the parameters measured is interesting and important as it indicates that people suffering more (more symptoms = more danger of progressing to 'severe') are much more likely to improve with leronlimab; 50% vs. 20%! and p = 0.0223.

Hopefully FDA will give EUA with a phase 4. It would certainly help open schools and keep them open!